Evolving role of regorafenib for the treatment of advanced cancers

Regorafenib is an oral tyrosine kinase inhibitor (TKI) approved for patients with treatment-refractory metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib, and unresectable hepatocellular carcinoma (HCC) following sorafenib [1,2]. Initially, regorafenib was approved for mCRC based on improved overall survival (OS) in the randomized, placebo-controlled, phase 3 CORRECT trial [3], which was confirmed in an expanded population of Asian patients in the randomized, double-blind, placebo-controlled phase 3 CONCUR trial [4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research